Neuroperipheral therapy stimulates peripheral nerves with body-worn electronics and has the potential to treat chronic diseases non-invasively. Cala Health is working on a treatment for Essential Tremor (ET), a movement disorder that makes it difficult to perform daily activities like eating and writing. Cala Health supports the International Essential Tremor Foundation (IETF).
In December 2018, Cala Health launched a clinical trail for its wrist-worn neurostimulator in treatment of ET. Their Cala One device achieved FDA clearance in April 2018 for transient relief in adults of ET. The clinical trial has 500 patients in a single-arm Prospect trial which will evaluate the Cala Two device at relieving symptoms for three months, with treatments twice per day at 40 minutes each.
VP, Commercial Operations
VP of Product Development and Operations
Kate Rosenbluth, PhD
Chief Marketing Officer
VP of Clinical Affairs
Scott Wilson, PhD
VP of Quality Assurance and Regulatory Affairs
Documentaries, videos and podcasts